Evaluación económica del tratamiento médico de la hiperplasia benigna de próstata (HBP) en España en atención especializada: Aplicación al coste-efectividad de dos fármacos habitualmente utilizados en su tratamiento

Carballido, J.; Ruiz-Cerdá, J.L.; Unda, M.; Baena, V.; Campoy, P.; Manasanch, J.; Slof, J.

My SciELO

Custom services

Services on Demand

Journal

Article

Indicators

Cited by SciELO
Access statistics

Actas Urológicas Españolas

Print version ISSN 0210-4806

Abstract

CARBALLIDO, J. et al. Economic evaluation of medical treatment of benign prostatic hyperplasia (BPH) in the specialised care setting in Spain: Application to the cost-effectiveness of two drugs frequently used in its treatment. Actas Urol Esp [online]. 2008, vol.32, n.9, pp.916-925. ISSN 0210-4806.

Objectives: To develop a pharmacoeconomic study in order to know the average cost of BPH diagnosis and follow-up in Spain in the Urology Department setting from the perspective of the public health system, considering two frequently used drugs in the Spanish Healthcare environment, an alpha-blocker (tamsulosin) and the lipido-sterolic extract of Serenoa repens (Permixon^®). Material and methods: Direct healthcare costs of BPH diagnosis and treatment were determined for each clinical stage according to the International Prostate Symptom Score (IPSS): mild, moderate and severe. Data on the usage and unit costs of healthcare resources were obtained from a semi-structured interview with clinical experts. The clinical efficacy of the medical treatments was obtained from the PERMAL clinical study, where therapeutic equivalence between the two studied drugs was observed. Results: For patients treated in the Urology Department setting, the average annual cost of diagnostic tests and medical visits related to mild, moderate or severe BPH symptoms were, respectively, 124, 207, and 286. The average annual cost of the drugs, including adverse effects treatment, was 211 for Permixon^® and 346 for tamsulosin. Discussion: Costs of medical care of BPH increases with symptom intensity. Pharmacological treatment makes up a significant part of the diseases cost. According to the model used, treatment with Permixon^® is considerably more cost-effective than with tamsulosin, offering average yearly savings of 135 per patient.

Keywords : Benign prostatic hyperplasia; Cost effectiveness analysis; Drug therapy; Healthcare resources; Serenoa repens; Tamsulosin.

· abstract in Spanish · text in Spanish · Spanish (

pdf )